Study on the persistence of Zika virus (ZIKV) in body fluids of patients with ZIKV infection in Brazil

Information

  • Research Project
  • 9586368
  • ApplicationId
    9586368
  • Core Project Number
    R21AI139777
  • Full Project Number
    1R21AI139777-01
  • Serial Number
    139777
  • FOA Number
    PA-17-085
  • Sub Project Id
  • Project Start Date
    7/3/2018 - 5 years ago
  • Project End Date
    12/31/2019 - 4 years ago
  • Program Officer Name
    DEMPSEY, WALLA L
  • Budget Start Date
    7/3/2018 - 5 years ago
  • Budget End Date
    6/30/2019 - 5 years ago
  • Fiscal Year
    2018
  • Support Year
    01
  • Suffix
  • Award Notice Date
    7/3/2018 - 5 years ago
Organizations

Study on the persistence of Zika virus (ZIKV) in body fluids of patients with ZIKV infection in Brazil

Little is known about Zika virus (ZIKV) biology and its pathogenesis in humans. ZIKV has been detected in blood, urine, semen, cerebral spinal fluid, saliva, amniotic fluid, and breast milk. In most ZIKV infected individuals, the virus is detected in the blood from a several days to one week after the onset of symptoms and has also been found to persist longer in urine and semen. Sexual transmission of ZIKV has been recently documented. Without a more granular understanding of the kinetics of ZIKV infection across biologic compartments it will be difficult to devise rational measures to prevent the transmission of the virus. This will be an observational cohort study of men and women, aged 18 years and above, including symptomatic participants with positive reverse transcriptase-polymerase chain reaction (RT-PCR) test in blood and/or urine and their symptomatic or asymptomatic household/sexual contacts with positive RT-PCR in blood and/or urine. Specimens to be collected at pre-established intervals and tested for ZIKV RNA by RT-PCR are blood, semen, vaginal secretions, saliva, tears, sweat, urine, rectal swab, menstrual blood and breast milk (if applicable). Participants will be recruited from collaborating clinics in selected locations with high population density, high circulation of the virus, strong community network, and serviced by laboratory facilities with capacity to perform the necessary tests. All participants will be followed up for 12 months, to assess detectability at longer time intervals, reactivation or reinfection. Analyses of antibody response, including circulating immunoglobulins M and G (IgM and IgG), will be performed in parallel to RT-PCR tests. Plaque reduction neutralization test will be performed in specimens of participants who are found to be simultaneously positive for ZIKV and dengue. Specific analysis will be performed to determine if socio-demographic characteristics, comorbidities and co-infections influence the persistence of the virus in the body fluids.

IC Name
NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES
  • Activity
    R21
  • Administering IC
    AI
  • Application Type
    1
  • Direct Cost Amount
    160650
  • Indirect Cost Amount
    12852
  • Total Cost
    173502
  • Sub Project Total Cost
  • ARRA Funded
    False
  • CFDA Code
    855
  • Ed Inst. Type
  • Funding ICs
    NIAID:173502\
  • Funding Mechanism
    Non-SBIR/STTR RPGs
  • Study Section
    ZRG1
  • Study Section Name
    Special Emphasis Panel
  • Organization Name
    FUNDACAO OSWALDO CRUZ
  • Organization Department
  • Organization DUNS
    899294177
  • Organization City
    RIO DE JANEIRO
  • Organization State
  • Organization Country
    BRAZIL
  • Organization Zip Code
    21040-360
  • Organization District
    BRAZIL